Drug Trial Radar · NCT00131404
A Two Year Safety and Efficacy Study in Obese Patients (0364-015)(TERMINATED)
Last checked: Nov 19, 2026Latest source record: Feb 5, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2,400
Actual
Start
Sep 2005
Primary completion
Feb 2007
Study completion Dec 2008
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Aug 18, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to determine the safety and efficacy of an investigational drug in patients with obesity plus extension.
Conditions
- Obesity
Interventions
taranabantDrug
taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule once daily. 52 week treatment period.
Comparator: PlaceboDrug
Placebo capsule once daily. 52 week treatment period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Decreases body weight; safety and tolerabilityTime frame: 156 Weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.